136 related articles for article (PubMed ID: 19797013)
21. Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis.
Oliveira JB; Baruffi R; Petersen CG; Mauri AL; Cavagna M; Franco JG
Reprod Biol Endocrinol; 2010 Sep; 8():107. PubMed ID: 20825643
[TBL] [Abstract][Full Text] [Related]
22. Endocrine modifications associated with final oocyte maturation with gonadotropin-releasing hormone agonists vs. human chorionic gonadotropin in women undergoing intrauterine insemination.
Díaz I; Guillén A; Pacheco A; Requena A; Garcia-Velasco JA
J Reprod Med; 2008 Jan; 53(1):33-9. PubMed ID: 18251359
[TBL] [Abstract][Full Text] [Related]
23. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
[TBL] [Abstract][Full Text] [Related]
24. Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial.
Urman B; Ata B; Yakin K; Alatas C; Aksoy S; Mercan R; Balaban B
Hum Reprod; 2009 Jul; 24(7):1640-7. PubMed ID: 19357135
[TBL] [Abstract][Full Text] [Related]
25. Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study.
Dal Prato L; Borini A; Coticchio G; Cattoli M; Flamigni C
Hum Reprod; 2004 Oct; 19(10):2200-5. PubMed ID: 15271868
[TBL] [Abstract][Full Text] [Related]
26. Luteal phase support with GnRH-a improves implantation and pregnancy rates in IVF cycles with endometrium of Qublan H; Amarin Z; Al-Qudah M; Diab F; Nawasreh M; Malkawi S; Balawneh M
Hum Fertil (Camb); 2008 Mar; 11(1):43-7. PubMed ID: 18320439
[TBL] [Abstract][Full Text] [Related]
27. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
[TBL] [Abstract][Full Text] [Related]
28. Does luteal estradiol supplementation have a role in long agonist cycles?
Elgindy EA; El-Haieg DO; Mostafa MI; Shafiek M
Fertil Steril; 2010 May; 93(7):2182-8. PubMed ID: 19243745
[TBL] [Abstract][Full Text] [Related]
29. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
[TBL] [Abstract][Full Text] [Related]
30. GnRH agonist (buserelin) or HCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Engmann L; Benadiva C
Hum Reprod; 2005 Nov; 20(11):3258-60; author reply 3260. PubMed ID: 16246862
[No Abstract] [Full Text] [Related]
31. Greater implantation and pregnancy rates with vaginal progesterone in intracytoplasmic sperm injection but not in in vitro fertilization cycles: a retrospective study.
Manno M; Marchesan E; Cicutto D; Zadro D; Favretti C; Tomei F
Fertil Steril; 2005 May; 83(5):1391-6. PubMed ID: 15866574
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients.
Hompes PG; Broekmans FJ; Hoozemans DA; Schats R;
Fertil Steril; 2008 Jun; 89(6):1685-93. PubMed ID: 17681325
[TBL] [Abstract][Full Text] [Related]
33. [Effect of luteal-phase gonadotropin-releasing hormone agonist administration on pregnancy outcome in IVF/ICSI cycles: a systematic review and Meta-analysis].
Yu LP; Liu N; Liu Y
Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):850-858. PubMed ID: 27916070
[No Abstract] [Full Text] [Related]
34. Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: a randomized double-blind clinical trial (NCT00461916).
Safdarian L; Mohammadi FS; Alleyassin A; Aghahosseini M; Meysamie A; Rahimi E
Hum Reprod; 2007 Sep; 22(9):2449-54. PubMed ID: 17635844
[TBL] [Abstract][Full Text] [Related]
35. Comparison between "short" and "long" protocols in an ICSI programme.
Loutradis D; Stefanidis K; Drakakis P; El Sheikh A; Milingos S; Antsaklis A; Michalas S
Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):69-72. PubMed ID: 15866089
[TBL] [Abstract][Full Text] [Related]
36. The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives.
Humaidan P; Papanikolaou EG; Kyrou D; Alsbjerg B; Polyzos NP; Devroey P; Fatemi HM
Reprod Biomed Online; 2012 Feb; 24(2):134-41. PubMed ID: 22197130
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the efficacy of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support in blastocyst stage embryo transfers.
Wang LJ; Huang FJ; Kung FT; Lin PY; Chang SY; Lan KC
Taiwan J Obstet Gynecol; 2009 Dec; 48(4):375-9. PubMed ID: 20045758
[TBL] [Abstract][Full Text] [Related]
38. Effect of Gonadotrophin-Releasing Hormone Agonist Addition for Luteal Support on Pregnancy Outcome in vitro Fertilization/Intracytoplasmic Sperm Injection Cycles: A Meta-Analysis Based on Randomized Controlled Trials.
Ma X; Du W; Hu J; Yang Y; Zhang X
Gynecol Obstet Invest; 2020; 85(1):13-25. PubMed ID: 31422404
[TBL] [Abstract][Full Text] [Related]
39. Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols for in vitro fertilisation and embryo transfer.
Depalo R; Lorusso F; Palmisano M; Bassi E; Totaro I; Vacca M; Trerotoli P; Masciandaro P; Selvaggi L
Gynecol Endocrinol; 2009 May; 25(5):328-34. PubMed ID: 19340626
[TBL] [Abstract][Full Text] [Related]
40. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
Kolibianakis EM; Schultze-Mosgau A; Schroer A; van Steirteghem A; Devroey P; Diedrich K; Griesinger G
Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
